3rd How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
September 26-28, 2025 – Stockholm, Sweden
Chairs: Caron Jacobson (Boston), Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)

Friday, September 26, 2025

08:30-08:40	**Welcome**	Conference Chairpersons
	SESSION I – Non-hodgkin lymphoma **Chair: Caron Jacobson (Boston)**	
08:40-08:50	Interactive case Follicular lymphoma & transformed follicular lymphoma	Caron Jacobson (Boston)
08:50-09:10	Case-based lecture FL - role of CAR-T and bispecifics	Catherine Thieblemont (Paris)
09:10-09:15	*Discussion*	
09:15-09:35	Case-based lecture tFL - relapsed after CAR-T: options	Caron Jacobson (Boston)
09:35-09:40	*Discussion*	
09:40-10:00	Case-based lecture (t)FL – consolidation/allo transplantation	Yasmina Serroukh (Rotterdam)
10:00-10:05	*Discussion*	
10:05-10:10	Brief Oral Communication Safety and efficacy of mosunetuzumab subcutaneous maintenance following mosunetuzumab plus lenalidomide induction therapy in previously untreated follicular lymphoma	Angel Serna Pareja (Barcelona)
10:10-10:13	*Discussion*	
10:13-10:35	*Panel discussion*	
10:35-11:05	***Coffee Break***	
	SESSION II – Multiple myeloma **Chair: Monique Minnema (Utrecht)**	
11:05-11:15	Interactive case High-risk myeloma	Monique Minnema (Utrecht)
11:15-11:35	Case-based lecture Multiple myeloma and bispecifics, as a bridge pre-CAR-T and a destination therapy	Monique Minnema (Utrecht)
11:35-11:40	*Discussion*	

11:40-12:00	Case-based lecture Multiple myeloma and CAR-T	Saad Usmani (New York)
12:00-12:05	*Discussion*	
12:05-12:25	Case-based lecture Next generation of CARs and bispecifics in clinical trials	Niels van de Donk (Amsterdam)
12:25-12:30	*Discussion*	
12:30-12:35	Brief Oral Communication Efficacy of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: a multicenter real-world analysis	Markus Maulhardt (Goettingen)
12:35-12:38	*Discussion*	
12:38-13:00	*Panel discussion*	
13:00-14:30	***Lunch***	

SESSION III – Novel indications of CAR T-cell therapy
Chair: Marie José Kersten (Amsterdam)

14:30-14:40	Interactive case Refractory classic Hodgkin lymphoma	Marie José Kersten (Amsterdam)
14:40-15:00	Case-based Lecture CAR-T and bispecifics in cHL and TCL	Carlos Ramos (Houston)
15:00-15:05	*Discussion*	
15:05-15:25	Case-based lecture CAR-T in other iNHL: road to approval?	Catherine Thieblemont (Paris)
15:25-15:30	*Discussion*	
15:30-15:50	Case-based lecture CAR-T in autoimmune disease	Hans Ulrich Scherer (Leiden)
15:50-15:55	*Discussion*	
15:55-16:00	Brief Oral Communication Glofitamab combined with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma: final results from the NP40126 study	Max Topp (Würzburg)
16:00-16:03	*Discussion*	
16:03-16:25	*Panel discussion*	
16:25-16:55	***Coffee break***	

16:55-17:35 DEBATE 1 – CAR-T vs bispecific antibody in multiple myeloma
Chair: Niels van de Donk (Amsterdam)

Audience votes

16:55-17:10 Pro CAR-T — Saad Usmani (New York)

17:10-17:25 Pro bispecific antibody — Monique Minnema (Utrecht)

17:25-17:35 *Discussion*

Audience votes again

17:35-18:35 ROUNDTABLE 1 – Access to CAR-T and bispecific across the globe
Chair: Marie José Kersten (Amsterdam)

17:35-17:40 Asia — Michelle Poon (Singapore)

17:40-17:45 Europe — Marie José Kersten (Amsterdam)

17:45-17:50 Africa — Candice Hendricks (Pretoria)

17:50-17:55 Central/South America — Lucila Nassif Kerbauy (Sao Paulo)

17:55-18:35 *Discussion*

18:45-20:00 ***Poster Walk and Welcome get-together buffet for all***
Poster Walk Leaders: Monique Minnema (Utrecht), Kai Rejeski (Munich)

Saturday, September 27, 2025

08:00-09:00 3 Simultaneous Meet the Expert sessions

1. Late complications of CAR-T Therapies — Kai Rejeski (Munich)
2. Immunomonitoring for CAR-Ts and bispecifics — Marion Subklewe (Munich)
3. Point of care production — Alvaro Urbano-Ispizua (Barcelona)

09:10-09:50 Keynote lecture
Chair: Caron Jacobson (Boston)

09:10-09:40 Mechanism of action and resistance to bispecifics — Marion Subklewe (Munich)
09:40-09:50 Discussion

09:50-10:20 Coffee Break

SESSION IV – Predictors of response and toxicity of CAR and bispecific
Chair: Frederick Locke (Tampa)

10:20-10:30 Interactive case — Frederick Locke (Tampa)
Relapse at 6m after CD19 CAR: possible mechanisms of resistance

10:30-10:50 Case-based lecture — Johannes Huppa (Berlin)
Antigen recognition via TCRs, CARs, and TcEs - insights from molecular imaging
10:50-10:55 *Discussion*

10:55-11:15 Case-based lecture — Maik Luu (Würzurg)
The role of the microbiome

11:15-11:20	*Discussion*	
11:20-11:40	Case-based lecture Neurologic toxicity following BCMA CAR-T and bispecifics	Philipp Karschnia (Erlangen)
11:40-11:45	*Discussion*	
11:45-12:05	Case-based lecture Cytopenias and infections post-CAR-T and bispecifics	Kai Rejeski (Munich)
12:05-12:10	*Discussion*	
12:10-12:30	Case-based lecture T-cell and other malignancies post-CAR T-cell therapy	Guido Ghilardi (Bellinzona)
12:30-12:35	*Discussion*	
12:35-12:40	Brief Oral Communication Impact of holding/bridging therapy on clinical, biological and metabolical response to CAR-T cells (axi-cel and liso-cel) in L2 LBCL	Lucie Laemmel (Pessac)
12:40-12:43	*Discussion*	
12:43-13:05	*Panel discussion*	
13:05-14:35	***Lunch***	
14:35-15:25	**ROUNDTABLE 2 – Access issues in CAR T-cell treatment** **Chair: Ulrich Jäger (Vienna)**	
14:35-14:40	Global access and intranational access based on socioeconomics/geographic distribution	Jonathan Clark (Loosdrecht)
14:40-14:45	Sequencing and selection criteria of patients: local practice preferences	Ulrich Jäger (Vienna)
14:45-14:50	Age and comorbidities and impact on patient selection	Roch Houot (Rennes)
14:50-14:55	Patient perspective	Jonathan Clark (Loosdrecht)
14:55-15:25	*Discussion*	
15:25-16:05	**DEBATE 2 – 1st line high-risk large B-cell lymphoma: which randomized controlled trial would you prioritize for your patient?** **Chair: Ulrich Jäger (Vienna)**	
Audience votes		
15:25-15:40	CAR-T RCT	Caron Jacobson (Boston)
15:40-15:55	Bispecific RCT	Max Topp (Würzburg)
15:55-16:05	*Discussion*	
Audience votes again		
16:05-16:35	***Coffee break***	

SESSION V- Real world data for CAR-T and bispecific
Chair: Kai Rejeski (Munich)

16:35-16:50	Real world data on bispecifics in LBCL	Max Topp (Würzburg)
16:50-17:05	CIBMTR CAR review: MCL and iNHL	Caron Jacobson (Boston)
17:05-17:20	LYSA CAR review: survivorship issues	Roch Houot (Rennes)
17:20-17:35	UK CAR review: B-ALL	Claire Roddie (London)
17:35-17:50	German CAR review: Bridging in LBCL and MCL	Peter Dreger (Heidelberg)
17:50-18:05	Spanish CAR review: sequencing therapies	Pere Barba (Barcelona)
18:05-18:35	*Panel discussion*	

Sunday, September 28, 2025

08:30-09:30 3 Simultaneous Meet the Expert Sessions

1.	Sequencing therapies in multiple myeloma	Saad Usmani (New York)
2.	Sequencing therapies in lymphoma	Max Topp (Würzburg)
3.	In vitro and in vivo models for CAR T efficacy and toxicity	Maik Luu (Würzurg) Marco Ruella (Philadelphia)

SESSION VI – Next Generation of CAR T-cell and bispecific antibody therapy
Chair: Claire Roddie (London)

09:40-10:00	Case-based lecture Novel CAR targets	Anne Marijn Kramer (Stanford)
10:00-10:05	*Discussion*	
10:05-10:25	Case-based lecture Pioneers of academic CAR T production	Alvaro Urbano-Ispizua (Barcelona)
10:25-10:30	*Discussion*	
10:30-10:50	Case-based lecture Allogeneic CAR-T	Frederick Locke (Tampa)
10:50-10:55	*Discussion*	
10:55-11:00	Brief Oral Communication Optimization of CAR-T Manufacturing for Multiple Myeloma: Impact of Culture Parameters on T-Cell Differentiation, Exhaustion Profile, and Cytotoxic Function	Emilia Jaskula (Wroclaw)
11:00-11:03	*Discussion*	
11:03- 11:25	*Panel discussion*	

11:25-12:05	**Keynote lecture** **Chair: Johannes Huppa (Berlin)**	
11:25-11:55	Outsmarting the Escape Artist: resistance to CART immunotherapy	Marco Ruella (Philadelphia)
11:55-12:05	Discussion	
12:05-12:15	***Closing remarks***	Conference Chairpersons

MEETING CLOSURE